Suprax
Suprax Medication Information:
Suprax medication comes in several different strengths; click on the strength you need to view prices from pharmacies competing to earn your business.
|
Suprax 100mg/5mL
|
Suprax 400 mg
|
Pharmacology
Pharmacokinetics
Following oral dosing, cefixime attains peak serum levels in approximately 4 hours. The half-life is about 3 to 4 hours and is not dose dependent. Cefixime is excreted by renal and biliary mechanisms. About 50% of the absorbed dose is excreted unchanged in the urine within 24 hours. There is no evidence of metabolism of cefixime in vivo.
Indications
Treatment of the following infections caused by susceptible strains of the designated microorganisms:
Middle Ear: Otitis media caused by S. pneumoniae, H. influenzae (beta-lactamase positive and negative strains), M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains) and S. pyogenes.
Paranasal Sinuses: Sinusitis caused by S. pneumoniae, H. influenzae (beta-lactamase positive and negative strains), and M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains).
Urinary Tract: Acute uncomplicated cystitis and urethritis caused by E. coli, P. mirabilis, and Klebsiella species.
Upper Respiratory Tract: Pharyngitis and tonsillitis caused by S. pyogenes.
Lower Respiratory Tract: Acute bronchitis caused by S. pneumoniae, M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains) and H. influenzae (beta-lactamase positive and negative strains).
Urinary Tract: Acute uncomplicated cystitis and urethritis caused by E. coli, P. mirabilis, and Klebsiella species.
Uncomplicated Gonorrhea: Uncomplicated gonorrhea (cervical/urethral and rectal) caused by N. gonorrhoeae, including penicillinase (beta-lactamase-positive) and nonpenicillinase (beta-lactamase-negative) producing strains.
Appropriate cultures should be taken for susceptibility testing before initiating treatment with cefixime. If warranted, therapy may be instituted before susceptibility results are known; however, once these are obtained, therapy may need to be adjusted.
Precautions
Labor and Delivery
Cefixime has not been studied for use during labor and delivery.
Lactation
It is not known whether cefixime is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cefixime is administered to a nursing woman.
Children
Safety and effectiveness of cefixime in children less than 6 months old have not been established.
General
If an allergic reaction to cefixime occurs, the drug should be discontinued, and, if necessary, the patient should be treated with appropriate agents, e.g., pressor amines, antihistamines, or corticosteroids. The possibility of the emergence of resistant organisms which might result in overgrowth should be kept in mind, particularly during prolonged treatment. In such use, careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Broad-spectrum antibiotics such as cefixime should be prescribed with caution in individuals with a history of gastrointestinal disease.
Once daily dosing only must be used for urinary tract infections, since twice daily dosing was shown to be not as effective in clinical studies.
Do not use cefixime to treat S. aureus as this strain of staphylococci is resistant to cefixime.
Renal Impairment: Cefixime may be administered in the presence of impaired renal function, but dose modification is recommended for patients with moderate or severe renal impairment (i.e., creatinine clearance of <40 mL/min) (see Dosage).
Bioavailability Differences Between Tablet and Suspension: The area under the time versus concentration curve is greater by approximately 26.4% and the Cmax is greater by approximately 20.7% with the oral suspension when compared to the tablet after doses of 400 mg. This increased absorption should be taken into consideration if the oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, tablets should not be substituted for oral suspension particularly in the treatment of otitis media where clinical trial experience with the suspension only is available (see Dosage).
Drug/Laboratory Interactions: A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
The administration of beta-lactams may result in a false-positive reaction for glucose in the urine using Clinitest, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix) be used.
A false-positive direct Coombs test has been reported during treatment with cephalosporin antibiotics; therefore, it should be recognized that a positive Coombs test may be due to the drug.
Pregnancy
The safety of cefixime in the treatment of infection in pregnant women has not been established.
Reproduction studies have been performed in mice and rats at doses up to 400 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefixime. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the likely benefits of using cefixime outweighs the potential risk to the fetus and/or the mother.
Supplied
Tablets
Each biconvex, oblong, white film-coated tablet, with rounded flattened corners, breaking scores on both sides and engraved EM 400 on one side, contains: cefixime 400 mg. The 400 mg tablet can be split into two equal parts of 200 mg. Nonmedicinal ingredients: calcium phosphate dibasic dihydrate, hydroxypropyl methylcellulose, light mineral oil, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate and titanium dioxide. Gluten- and lactose-free. Blister packs of 7 tablets and 2×5 tablets.
Store at controlled room temperature 15 to 30°C.
Powder for Oral Suspension
Each 5 mL of reconstituted suspension contains: cefixime 100 mg. Nonmedicinal ingredients: artificial strawberry flavor, sodium benzoate, sucrose and xanthan gum. Gluten- and lactose-free. Bottles of 50 mL.
Contraindications
Patients with known allergies to the cephalosporin or penicillin antibiotics.
Warnings
In penicillin-sensitive patients, cefixime should be administered cautiously. Patients may be sensitive to penicillins and not to cephalosporins such as cefixime or be sensitive to both. Medical literature indicates that patients sensitive to cephalosporins are very likely to be penicillin sensitive.
Antibiotics, including cefixime, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.
C. difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including SUPRAX. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.
If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against C. difficile. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against C. difficile. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases.
Adverse Effects
Renal
transient elevations in Blood Urea Nitrogen (BUN) or creatinine.
Other Adverse Events including Post-Marketing Surveillance Data
The following adverse reactions have been reported following the use of cefixime. Incidence rates were less than 1 in 50 (less than 2%), except as otherwise noted.
Gastrointestinal
diarrhea (15%), stool changes (12%), nausea (9%), abdominal pain (5%), dyspepsia (3%), flatulence (3%) and vomiting (2%).
Pseudomembranous colitis has been reported rarely.
Hypersensitivity
skin rashes, drug fever and pruritus. Anaphylactic reactions (urticaria and angioedema) have been reported rarely.
Skin
Bullous skin reactions (erythema multiforme and Stevens-Johnson syndrome) have been reported very rarely.
In addition to the adverse reactions listed above which have been observed in patients treated with cefixime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics. Allergic reactions were reported including anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, and hemorrhage. Abnormal laboratory tests were reported including positive Coombs test, elevated bilirubin, elevated LDH, pancytopenia, neutropenia and agranulocytosis.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see Dosage and Overdose). If seizures associated with cefixime occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Central Nervous System
headaches (11%) and dizziness (3%).
Other
Genital pruritus, vaginitis and candidiasis has been reported.
Clinical Trials
Five percent of patients in the clinical trials discontinued therapy because of drug-related adverse reactions. Thirty-six percent of the pediatric patient population experienced at least one adverse reaction (mild 25%, moderate 9%, severe 2%). Forty-seven percent of the adult patients experienced at least one adverse reaction (mild 24%, moderate 19%, severe 4%). The most commonly seen adverse reactions in the clinical trials of the tablet formulation were gastrointestinal events, which were reported in 37% of all adult patients treated (mild 21%, moderate 13%, severe 3%). The predominant adverse events seen in adults in clinical trials with cefixime were diarrhea 15%, (mild 7.2%, moderate 6.2%, severe 1.5%), headache 11%, stool changes 12%, nausea 9%, abdominal pain 5%, and dyspepsia 3%. The rates of the most prevalent adverse reactions were similar in the once a day and twice a day dosing regimens with the exception of headache which appears slightly more frequently in adults dosed once a day (12.9%) versus twice a day (8%). Other than for generally mild rashes or emesis which were each observed in 5% of children treated, the incidence of adverse reactions in pediatric patients receiving the suspension was generally comparable to the incidence seen in adult patients receiving tablets.
These symptoms usually responded to symptomatic therapy or ceased when cefixime was discontinued.
Several patients developed severe diarrhea and/or documented pseudomembranous colitis, and a few required hospitalization.
When cefixime was used as single 400 mg dose therapy in clinical trials in the treatment of uncomplicated gonorrhoea, adverse reactions which were considered to be related to cefixime therapy, were reported for 5.9% (21/358) of patients. Clinically mild gastrointestinal side effects occurred in 3.7% of all patients, moderate events occurred in 0.9% of all patients and no adverse reactions were reported as severe. Individual event rates included diarrhea 1% and loose or frequent stools 1%. Incidence rates for all other adverse reactions reported for adults in these trials were less than 1%.
Hemic and Lymphatic
transient thrombocytopenia, thrombocytosis, leukopenia, eosinophilia, neutropenia and agranulocytosis. Prolongation in prothrombin time was seen rarely.
Hepatic
transient elevations of AST, ALT and alkaline phosphatase.
Overdose
Treatment
Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis.
Dosage
Suprax
Reconstitution Directions for Oral Suspensions
After mixing, the suspension may be kept for 14 days at room temperature or under refrigeration without significant loss of potency. Keep container tightly closed. Shake well before using. Discard unused portion after 14 days.
Adults
The recommended dose is 400 mg once daily. When necessary, a dose of 200 mg (one-half of a 400 mg tablet) given twice daily may be considered except for urinary tract infections where once daily dosing must be used.
For treatment of uncomplicated gonococcal infections, a single oral dose of 400 mg is recommended.